Sponsored by VMG Health | info@vmghealth.com | 214.369.4888

Pfizer to acquire Anacor in $4.5B deal

After calling off its deal with Allergan earlier this year, New York City-based Pfizer plans to buy Palo Alto, Calif.-based Anacor Pharmaceuticals in a deal worth approximately $4.5 billion, according to The Wall Street Journal.

Including debt, the deal, which is expected to close in the third quarter of this year, is valued around $5.2 billion.

Although Anacor currently doesn't have any products on the market, it has the rights to Kerydin, a treatment for toenail fungus, according to the report. Pfizer believes Kerydin and Anacor's other offerings would balance Pfizer's inflammation and immunology products.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars